Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2016 | The Medicines Adaptive Pathways to Patients (MAPPs) and its importance in oncology

Bettina Ryll • 7 Oct 2016
ESMO 2016
Skin Cancer

Bettina Ryll, MD, PhD of Melanoma Patient Network Europe talks about the role of drug development and clinical trials for oncology. Dr Ryll believes that the Medicines Adaptive Pathways to Patients (MAPPs) of the European Medicines Agency (EMA) is an important tool in oncology to combine early access to innovation with systematic learning.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.

More from Bettina Ryll

Impact of COVID-19 on melanoma treatment
3:02
Impact of COVID-19 on melanoma treatment
Bettina Ryll • 13 Oct 2020
Access to novel therapies in melanoma
3:25
Access to novel therapies in melanoma
Bettina Ryll • 14 Oct 2020
Melanoma Patient Network Europe
2:12
Melanoma Patient Network Europe
Bettina Ryll • 14 Oct 2020
ECCO 2017: treatment value vs affordability
2:05
ECCO 2017: treatment value vs affordability
Bettina Ryll • 27 Jan 2017

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals